Westfield Capital Management Co. LP Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

Westfield Capital Management Co. LP increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 1.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,226,771 shares of the biopharmaceutical company’s stock after acquiring an additional 20,705 shares during the period. Westfield Capital Management Co. LP’s holdings in Xenon Pharmaceuticals were worth $54,984,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in XENE. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals during the third quarter worth about $32,000. Blue Trust Inc. boosted its holdings in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Xenon Pharmaceuticals during the third quarter worth about $39,000. Osaic Holdings Inc. boosted its holdings in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,034 shares in the last quarter. Finally, State of Wyoming boosted its holdings in Xenon Pharmaceuticals by 112.8% during the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 610 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 2,771 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81. Following the transaction, the insider owned 4,729 shares of the company’s stock, valued at $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ian Mortimer sold 270,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $361,980. This represents a 97.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 296,707 shares of company stock valued at $17,845,365 over the last quarter. Company insiders own 4.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on XENE shares. Jefferies Financial Group set a $100.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. HC Wainwright boosted their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Wedbush decreased their price objective on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, March 16th. Finally, Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Stock Performance

Shares of XENE opened at $51.73 on Friday. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of -11.01 and a beta of 0.62. The company’s 50 day simple moving average is $55.83 and its 200 day simple moving average is $48.55. Xenon Pharmaceuticals Inc. has a 1 year low of $30.00 and a 1 year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the previous year, the company posted ($0.83) EPS. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.